Medicare Update: Coverage Could Change for Breast Cancer Patients
Summary
Medicare is considering ending coverage for certain breast cancer biomarker tests, including the DCISionRT test, which helps predict the risk of cancer returning and benefits of radiation therapy for early-stage breast cancer. Some doctors worry that losing this coverage could make treatment choices harder for patients, while Medicare says current evidence does not clearly show these tests work better than existing tools.Key Facts
- Medicare's MolDX program, managed by Palmetto GBA, proposes stopping payment for some DCIS biomarker tests.
- The DCISionRT test examines proteins in tumor tissue to help predict cancer return and guide radiation treatment decisions.
- DCIS (ductal carcinoma in situ) is a noninvasive breast cancer affecting over 60,000 women in the U.S. annually.
- Some doctors believe the test helps avoid unnecessary treatments and targets those needing more aggressive care.
- Medicare reviewed 57 studies and found no strong proof that these tests outperform current clinical methods.
- The decision affects Medicare-covered patients but not those with commercial insurance, who still have access to the tests.
- The issue represents broader questions about coverage for precision medicine, which tailors treatment to individual patients.
- Medicare aims to make sure any coverage decisions are based on strong evidence, not simply cost savings.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
